Tranilast
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Tranilast
Description :
Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM) . Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects[1]. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells[2].Product Name Alternative :
MK-341; SB 252218UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Angiotensin Receptor; Prostaglandin ReceptorType :
Reference compoundRelated Pathways :
GPCR/G ProteinApplications :
COVID-19-immunoregulationField of Research :
Inflammation/Immunology; Endocrinology; Cancer; Cardiovascular DiseaseAssay Protocol :
https://www.medchemexpress.com/Tranilast.htmlPurity :
99.95Solubility :
DMSO : 50 mg/mL (ultrasonic)Smiles :
O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC=C(OC)C(OC)=C2)=OMolecular Formula :
C18H17NO5Molecular Weight :
327.33Precautions :
H302, H315, H319, H335References & Citations :
[1]K Ikai , et al. Inhibitory Effect of Tranilast on Prostaglandin D Synthetase. Biochem Pharmacol. 1989 Aug 15;38 (16) :2673-6.|[2]Sara Darakhshan, et al. Tranilast Enhances the Anti-Tumor Effects of Tamoxifen on Human Breast Cancer Cells in Vitro. J Biomed Sci. 2013 Oct 21;20 (1) :76.|[3]E A Capper, et al. Modulation of Human Monocyte Activities by Tranilast, SB 252218, a Compound Demonstrating Efficacy in Restenosis. J Pharmacol Exp Ther. 2000 Dec;295 (3) :1061-9.|[4]M Isaji , et al. Tranilast Inhibits the Proliferation, Chemotaxis and Tube Formation of Human Microvascular Endothelial Cells in Vitro and Angiogenesis in Vivo. Br J Pharmacol. 1997 Nov;122 (6) :1061-6.|[5]K Miyazawa , et al. Tranilast Antagonizes Angiotensin II and Inhibits Its Biological Effects in Vascular Smooth Muscle Cells. Atherosclerosis. 1996 Apr 5;121 (2) :167-73.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
DPCAS Number :
[53902-12-8]

